Search for: [Abstract = "Introduction. Perianal fistulas are present in 20\-40% of Crohn’s patients, causing great discomfort and significant compromising quality of life. Biologic therapy showed highest success rate in the treatment of fistulizing Crohn’s disease. Aim of study. To estimate efficacy of combined surgical and biological treatment of fistulizing perianal Crohn’s disease. Material and methods. 34 patients with confirmed perianal, fistulizing Crohs’s disease were operated in the IIIrd Department of general Surgery between 2007 and 2009. 21 patients underwent biological treatment with anti\-TNF\-α antibodies. 13 remaining patients were included to the control group. Every patient from both study and control group underwent fistulography, rectoscopy and endorectal ultrasound examination \(ERUS\). EUA with excision of external orifice and fistulectomy with non\-cuting seton placement were done. Afterwards patients, which fulfilled the inclusion criteria were included to biologic treatment with infliximab. The ssessments were after 0, 6, 10, 30 and 54 weeks. Results. After 54 weeks of combined modality treatment, closing of 76,1% draining perianal fistulas was observed in study group, while in control group only 36,3% \(p<0,01\). During further follow\-up, significant higher reduction of CDAI, PDAI, CRP level was observed \(p<0,05\). Correlation of CDAI and CRP was proved \(p<0,05\), esp"]

Number of results: 1